- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00386035
Effects of Two Anti-HIV Drug Regimens on HIV Transmission Risk Behavior Among SMART Study Participants
HIV Transmission Risk Behavior Substudy
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
It is important to consider the role that HIV infected individuals play in ongoing HIV transmission. Different anti-HIV treatment regimens may lead to variations in HIV transmission risk behavior among HIV infected individuals. HIV infected people with viral loads of less than 1,000 copies/ml are less likely to transmit HIV through heterosexual sex. However, condom use sometimes decreases after individuals start combination antiretroviral therapy (ART); also, some studies have shown an increased rate in acquiring sexually transmitted infections (STIs) following initiation of ART, and those on ART may transmit a drug-resistant strain of HIV. In the SMART study, participants were randomly assigned to one of two treatment groups:
- Group 1 participants will follow a drug conservation (DC) regimen in which ART will be stopped or deferred until CD4 cell count drops below 250 cells/mm3, will be initiated until CD4 cell count is at least 350 cells/mm3, and then will be followed by episodic ART based on CD4 cell count.
- Group 2 participants will follow a viral suppression (VS) regimen in which ART is continued to keep viral loads as low as possible, regardless of CD4 cell count.
The purpose of this study is to compare how the DC and VS regimens affect HIV transmission risk behavior among SMART study participants.
At baseline, participants will complete a questionnaire about their sexual behavior during the previous 2 months. They will also undergo urine and blood collection for STI testing. These same procedures will occur at Months 4 and 12, then every year thereafter for the first 4 years that a participant is in the parent study. Participants and their physicians will be notified of STI testing results so that patients can be referred to appropriate care.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
California
-
Beverly Hills, California, Stati Uniti, 90211
- AIDS Healthcare Foundation CRS
-
Fresno, California, Stati Uniti, 93702
- UCSF, Fresno, School of Medicine, Dept. of Internal Medicine CRS
-
Mill Valley, California, Stati Uniti, 94941-3013
- Dr. M. Estes Med. Practice CRS
-
Oakland, California, Stati Uniti, 94609
- Dr. Robert Scott Med. Practice CRS
-
Oakland, California, Stati Uniti, 94609
- East Bay AIDS Ctr. CRS
-
San Francisco, California, Stati Uniti, 94114
- Castro-Mission Health Ctr. CRS
-
San Francisco, California, Stati Uniti, 94102
- Dr. Shawn Hassler Med. Practice CRS
-
San Francisco, California, Stati Uniti, 94110
- Positive Health Program Clinic (San Francisco Gen. Hosp.) CRS
-
San Francisco, California, Stati Uniti, 94114-1010
- Dr. Virginia Cafaro Med. Practice CRS
-
San Francisco, California, Stati Uniti, 94114-1010
- Dr. William Owen Med. Practice CRS
-
San Francisco, California, Stati Uniti, 94121
- San Francisco VAMC, Infectious Diseases Clinic CRS
-
San Francisco, California, Stati Uniti, 94143
- UCSF PHP, Gen. Internal Medicine Practice CRS
-
-
Colorado
-
Boulder, Colorado, Stati Uniti, 80501-4507
- Beacon Clinic at Boulder CRS
-
Denver, Colorado, Stati Uniti, 80204-4507
- Univ. of Colorado Health Science Ctr. CRS
-
Denver, Colorado, Stati Uniti, 80205
- Eastside Family Health Ctr. CRS
-
Denver, Colorado, Stati Uniti, 80204
- Denver Public Health CRS
-
Denver, Colorado, Stati Uniti, 80204-4507
- Denver Infectious Diseases Consultants CRS
-
Denver, Colorado, Stati Uniti, 80204-4507
- Kaiser Permanente of Denver CRS
-
Denver, Colorado, Stati Uniti, 80204
- Denver Public Health CRS - INSIGHT
-
Denver, Colorado, Stati Uniti, 80220
- Denver VAMC CRS
-
Wheat Ridge, Colorado, Stati Uniti, 80033
- Western Infectious Disease Consultants CRS
-
-
District of Columbia
-
Washington, District of Columbia, Stati Uniti, 20422
- Washington DC VAMC, Washington Regional AIDS Program, Infectious Diseases CRS
-
-
Florida
-
Miami, Florida, Stati Uniti, 33125
- Miami VAMC CRS
-
-
Georgia
-
Decatur, Georgia, Stati Uniti, 30033
- Atlanta VAMC CRS
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48201
- Wayne State Univ. CRS
-
Detroit, Michigan, Stati Uniti, 48201
- Harper Hosp., Detroit CRS
-
Detroit, Michigan, Stati Uniti, 48201
- Wayne State Univ. INSIGHT CRS
-
Detroit, Michigan, Stati Uniti, 48215
- Detroit Community Health Connection, Inc. CRS
-
Grand Rapids, Michigan, Stati Uniti, 49503
- McAuley Health Ctr. CRS
-
-
New Jersey
-
Camden, New Jersey, Stati Uniti, 08103
- Cooper Univ. Hosp. CRS
-
Camden, New Jersey, Stati Uniti
- Cooper Hospital/Univ. Med. Ctr., The Cooper Early Intervention Program (EIP) CRS
-
Newark, New Jersey, Stati Uniti, 07103
- New Jersey Medical School- Adult Clinical Research Ctr. CRS
-
Somers Point, New Jersey, Stati Uniti, 08244
- South Jersey Infectious Disease, Cape Clinical Trials CRS
-
Voorhees, New Jersey, Stati Uniti, 08043
- The Early Intervention Program at Kennedy Hosp. CRS
-
-
New York
-
Bronx, New York, Stati Uniti, 10457
- Bronx-Lebanon Hosp. Ctr. CRS
-
Bronx, New York, Stati Uniti, 10452
- Bronx Prevention Center CRS
-
Bronx, New York, Stati Uniti, 10467
- Montefiore Med. Ctr., AIDS Ctr. CRS
-
New York, New York, Stati Uniti, 10011
- St. Vincent Hosp. & Med. Ctr. CRS
-
-
Oregon
-
Eugene, Oregon, Stati Uniti, 97401
- PeaceHealth Med. Group - Hilyard Street Clinic CRS
-
Portland, Oregon, Stati Uniti, 97227
- Kaiser Immune Deficiency Clinic of Portland CRS
-
Portland, Oregon, Stati Uniti, 97239
- Oregon Health & Sciences Univ. Internal Medicine (L-475) CRS
-
Portland, Oregon, Stati Uniti, 97210
- The Research & Education Group-Portland CRS
-
Portland, Oregon, Stati Uniti, 97204
- Multnomah County Health Dept., HIV Health Services Ctr. CRS
-
Portland, Oregon, Stati Uniti, 97210
- Legacy Clinic Good Samaritan CRS
-
Portland, Oregon, Stati Uniti, 97213
- Providence Portland Med. Ctr., Ambulatory Care and Education Ctr. CRS
-
Portland, Oregon, Stati Uniti, 97227
- Legacy Clinic Emanuel CRS
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19140
- Temple Univ. School of Medicine CRS
-
Philadelphia, Pennsylvania, Stati Uniti, 19107
- Philadelphia FIGHT - Dr. Jay Kostman CRS
-
Philadelphia, Pennsylvania, Stati Uniti, 19141
- Albert Einstein Med. Ctr., Immunodeficiency Ctr. CRS
-
-
Virginia
-
Fredericksburg, Virginia, Stati Uniti, 22401
- MediCorp, Infectious Disease Associates CRS
-
Mechanicsville, Virginia, Stati Uniti, 23116
- Hanover Med. Park (Mechanicsville, VA) CRS
-
Norfolk, Virginia, Stati Uniti, 23507
- Eastern Virginia Med. School, Ctr. for the Comprehensive Care of Immune Deficiency CRS
-
Petersburg, Virginia, Stati Uniti, 23803
- Petersburg Health Care Alliance CRS
-
Richmond, Virginia, Stati Uniti, 23224
- CrossOver Health Ctr. CRS
-
Richmond, Virginia, Stati Uniti, 23224
- South Richmond Health Care Ctr. CRS
-
Richmond, Virginia, Stati Uniti, 23249
- Hunter Holmes McGuire VAMC CRS
-
Richmond, Virginia, Stati Uniti, 23298
- VCU Health Systems, Infectious Disease Clinic CRS
-
Richmond, Virginia, Stati Uniti, 23223
- Vernon Harris East End Community Health Ctr. CRS
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Coenrollment in the SMART study
- Parent or guardian willing to provide informed consent, if applicable
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
---|---|
1: DC Group
HIV infected participants who will stop or defer ART until the CD4 cell count drops below 250 cells/mm3 and who discontinue ART when CD4 cell count reaches above 350 cells/mm3.
Participants are followed by episodic ART based on CD4 cell count.
|
Participants follow a drug conservation (DC) regimen in which ART is stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count is at least 350 cells/mm3, and then are followed by episodic ART based on CD4 cell count.
|
2: VS Group
HIV infected participants who continue ART to keep viral loads as low as possible, regardless of CD4 cell count.
|
Group 2 participants follow a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
To compare the DC group to the VS group for HIV transmission and risk behaviors
Lasso di tempo: At the end of study
|
At the end of study
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
To compare the VS group to the DC group on HIV transmission risk behavior in participants who are not on ART at enrollment
Lasso di tempo: At the end of study
|
At the end of study
|
To compare the effects of continuing ART in the VS group to stopping ART in the DC group on HIV transmission risk behavior among participants who are on ART at enrollment
Lasso di tempo: At the end of study
|
At the end of study
|
To evaluate the correlation between self-reported adherence to ART and HIV transmission risk behavior for participants on ART
Lasso di tempo: At the end of study
|
At the end of study
|
To compare the DC and VS groups for HIV transmission risk behavior in subgroups defined by age, gender, possible transmission category, HIV RNA level, and baseline genotypic resistance pattern.
Lasso di tempo: At the end of study
|
At the end of study
|
To evaluate the correlation between self-reported transmission risk behavior and the acquisition of certain sexually transmitted diseases as specified in the protocol.
Lasso di tempo: At the end of study
|
At the end of study
|
To develop analytic techniques to combine behavioral and biological data into a measure of overall transmission risk
Lasso di tempo: At the end of study
|
At the end of study
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Cattedra di studio: Wafaa El-Sadr, MD, MPH, Harlem AIDS Treatment Group, Harlem Hospital Center
- Cattedra di studio: James Neaton, PhD, CPCRA Statistical and Data Management Center/CCBR
Pubblicazioni e link utili
Pubblicazioni generali
- Bunnell R, Ekwaru JP, Solberg P, Wamai N, Bikaako-Kajura W, Were W, Coutinho A, Liechty C, Madraa E, Rutherford G, Mermin J. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS. 2006 Jan 2;20(1):85-92. doi: 10.1097/01.aids.0000196566.40702.28.
- Kozal MJ, Amico KR, Chiarella J, Schreibman T, Cornman D, Fisher W, Fisher J, Friedland G. Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care. AIDS. 2004 Nov 5;18(16):2185-9. doi: 10.1097/00002030-200411050-00011.
- Remien RH, Halkitis PN, O'Leary A, Wolitski RJ, Gomez CA. Risk Perception and sexual risk behaviors among HIV-positive men on antiretroviral therapy. AIDS Behav. 2005 Jun;9(2):167-76. doi: 10.1007/s10461-005-3898-7.
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Infezioni da virus a RNA
- Malattie virali
- Infezioni
- Infezioni a trasmissione ematica
- Malattie trasmissibili
- Malattie sessualmente trasmissibili, virali
- Malattie trasmesse sessualmente
- Infezioni da lentivirus
- Infezioni da retroviridae
- Sindromi da deficit immunologico
- Malattie del sistema immunitario
- Infezioni da HIV
Altri numeri di identificazione dello studio
- CPCRA 065B
- SMART
- 10113 (Identificatore di registro: DAIDS-ES)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Infezioni da HIV
-
University of MinnesotaRitiratoInfezioni da HIV | HIV/AIDS | HIV | AIDS | Problema di Aids/Hiv | AIDS e infezioniStati Uniti
-
Erasmus Medical CenterNon ancora reclutamentoInfezioni da HIV | HIV | Infezione da HIV-1 | Infezione da HIV IOlanda
-
Helios SaludViiV HealthcareSconosciutoHIV | Infezione da HIV-1Argentina
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement; Centre Pasteur du Cameroun e altri collaboratoriSconosciutoHIV | Bambini non infetti da HIV | Bambini esposti all'HIVCamerun
-
University of MinnesotaCompletatoInfezioni da HIV | HIV | ImmunodeficienzaStati Uniti
-
Allegheny Singer Research Institute (also known...Attivo, non reclutanteInfezioni da HIV | Infezione da HIV-1 | Infezione da HIV IStati Uniti
-
University of California, DavisCompletato
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completato
-
University of ZimbabweCompletato
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completato
Prove cliniche su Delayed ART
-
Asahi Kasei Pharma CorporationCompletatoCancro al colon in stadio II/III postoperatorioGiappone
-
Institute of Tropical Medicine, BelgiumUniversity Hospital, Ghent; Universitair Ziekenhuis Brussel; Agentschap voor Innovatie... e altri collaboratoriCompletato
-
Centre Francois BaclesseLigue contre le cancer, FranceCompletato
-
Kheth'ImpiloMinistry of Health and Child Welfare, Zimbabwe; EQUIP Innovation for Health; Organization... e altri collaboratoriSconosciuto
-
Tang-Du HospitalZhejiang University; Chipscreen Biosciences, Ltd.; First Affiliated Hospital of...SconosciutoInfezioni croniche da HIVCina
-
Asahi Kasei Pharma CorporationCompletatoFibrosi Polmonare IdiopaticaGiappone
-
University of WashingtonBill and Melinda Gates FoundationCompletatoHIV | ARTESud Africa, Uganda
-
Stanford UniversityRitirato
-
Asahi Kasei Pharma CorporationCompletatoCoagulazione intravascolare disseminataGiappone